Astellas Pharma (JP:4503) has released an update.
Astellas Pharma Inc. has announced that China’s National Medical Products Administration approved its drug XTANDI for metastatic hormone-sensitive prostate cancer, based on significant positive outcomes from Phase 3 ARCHES studies in both global and Chinese patient populations. XTANDI, when combined with androgen deprivation therapy, showed a substantial reduction in the risk of PSA progression, marking its third indication for advanced prostate cancer in China. This approval expands treatment options for Chinese patients and is already factored into Astellas’ financial forecast for the fiscal year ending March 31, 2025.
For further insights into JP:4503 stock, check out TipRanks’ Stock Analysis page.
